| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Leukemia | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | |||||
| 3 | More general conditions related to this trial | ||||
| Immune System Diseases | |||||
| Immunoproliferative Disorders | |||||
| Leukemia, Lymphoid | |||||
| Lymphatic Diseases | |||||
| Lymphoproliferative Disorders | |||||
| Neoplasms | |||||
| Neoplasms by Histologic Type | |||||
| 4 | Interventions listed in this trial | ||||
| cytarabine | |||||
| fludarabine phosphate | |||||
| idarubicin | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Fludarabine | |||||
| Fludarabine monophosphate | |||||
| 6 | More general drug interventions related to this trial | ||||
| Anti-Infective Agents | |||||
| Antibiotics, Antineoplastic | |||||
| Antimetabolites | |||||
| Antimetabolites, Antineoplastic | |||||
| Antineoplastic Agents | |||||
| Antiviral Agents | |||||
| Immunologic Factors | |||||
| Immunosuppressive Agents | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Therapeutic Uses | |||||
| 7 | Sponsors listed in this trial | ||||
| European Organization for Research and Treatment of Cancer | |||||
|
